Biotech Co.* (Symbol)

Agbiotech Partner (Country/Symbol)

Type/Product Area

Disclosed Funding (M)

Terms/Details (Date)

Affymax Technologies NV (subsidiary of Glaxo Wellcome plc [UK; NYSE:GLX])

DuPont Crop Protection (unit of DuPont [NYSE:DD])

Research and development collaboration/access to Affymax chemical libraries for testing against crop protection targets


Affymax will receive fees for compound access and testing, plus milestones and royalties on any products that emerge (2/00)

AgrBioTech Inc.

Research Seeds Inc.

Sale of assets/all assets of AgriBioTech's forage business unit


Research Seeds agreed to pay $16M in cash, subject to various pre-closing conditions (6/00)

AgriBioTech Inc.

Kenneth R. Budd (former COO and president of AgriBioTech) and J.R. Simplot Co.

Sale of assets/turfgrass seed assets and specialty division


Sale is subject to various closing condition (5/00)

Agrinomics LLC (50% owned subsidiary of Agritope Inc. [AGTO]) and Aventis CropScience (unit of Aventis SA [France; NYSE:AVE])

Vilmorin Clause & Cie (France) and Biotech M.A.H. Plant Genomic Fund (Israel)

Research collaboration/discovery of genes that confer desirable traits in vegetables


A Vilmorin/Biotech M.A.H. joint venture will sponsor the $7.5M research program; Agrinomics received $1.5M up front to fund the first year of research (2/00)

Aleurone Corp.*

Monsanto Co. (unit of Pharmacia Corp. [NYSE: PHA])

License/Aleurone's genetic engineering technology for cereal plants expressing foreign proteins in seed storage areas


Aleuron will receive up-front payment and royalties on sales (1/00)


ImmuCell Corp. (ICCC)

License/rights to AMBI's Wipe Out product, consisting of pre-moistened towelettes impregnated with nisin to clean, santize and dry the teat area of a cow prior to milking


ImmuCell paid $0.36M to acquire equipment, trademarks and a license; ImmuCell also agreed to manufacture and supply nisin to AMBI as needed (1/00)


ImmuCell Corp. (ICCC)

License/rights to develop and market new antibacterial drugs for animals using nisin and lysostaphin technologies


AMBI received an up-front payment and will receive milestones and royalties on any sales (4/00)

Atrix Laboratories Inc. (ATRX)

Pharmacia Corp. (NYSE:PHA)

Marketing/periodontal therapy for companion animals


Pharmacia's animal health unit will market periodontal gel containing doxycycline for use in companion animals; Heska Corp. was formerly marketing partner for the product; Atrix will continue manufacturing the gel (4/00)

AviGenics Inc.*

Demegen Inc. (OTC BB:DBOT)

Research and development collaboration/development of chickens resistant to coccidiosis and other avian enteric diseases such as Salmonella and Campylobacter infections


ND (1/00)

BioFocus plc (UK)

Aventis CropScience (unit of Aventis SA [France; NYSE:AVE])

Research collaboration/BioFocus will design and supply compounds for agricultural applications


BioFocus gains access to new facility; further details ND (3/00)

Bioject Medical Technologies (BJCT)

Animal Medical Center of New York

Provider agreement/use of Bioject's needle-free injectable DNA-based melanoma vaccine in animals


Animal Medical will be the exclusive provider of the product for use in animals (4/00)

Celera AgGen (unit of Celera Genomics [NYSE:CRA])

ViaLactia Biosciences New Zealand Ltd.

Research collaboration/Celera will seek to discover new bovine genes important for increasing dairy productivity


All intellectual property will be jointly owned (4/00)

CRS Robotics Corp. (Canada; TSE:ROB)

Monsanto Co. (unit of Pharmacia Corp.; [NYSE: PHA])

Supply agreement/CRS will design and provide automated lab systems for high-throughput genotyping


Immediate order, with a value of $1.2M, covers first two systems (5/00)

Devgen NV* (Belgium)


Expansion of research collaboration/Devgen is discovering targets of existing insecticides and will use the information to make insecticides more target-specific; a second part of the program involves putting candidate targets into C. elegans and using them to screen for novel insecticides


Expansion of 11/99 deal following faster-than-expected progress; Devgen will receive $15M in committed research and development fees over three years, plus milestones and royalties (4/00)

Diversa Corp. (DVSA)

Aventis Animal Nutrition SA (unit of Aventis SA [France; NYSE:AVE])

Extension of research collaboration/development of a biocatalytic process to manufacture an Aventis product for animal nutrition


Based on progress to date, companies extended initial six-month agreement, resulting in additional research funding to Diversa (4/00)

Enchira Biotechnology Corp. (formerly Energy Biosystems; ENBC)

Genencor International Inc.*

License/Enchira's gene-shuffling technology for development of gene-based products for various industries, including grain processing, animal feed and food ingredients


Licensing agreement is the first of what is expected to be several deals between the companies(5/00)

EnviroLogix Inc.*

Aventis CropScience (unit of Avents SA [France; NYSE: AVE])

License/tests for genetically modified organisms


EnviroLogix will have access to Aventis' BAR and PAT herbicide-resistance proteins and to Cry9C (a Bt protein); further details ND (3/00)

Exelixis Pharmaceuticals Inc. (EXEL)

Bayer AG (Germany)

Joint venture/discovery of insecticides and nematicides based on targets discovered by Exelixis using model system genomics


Companies formed GenOptera LLC under terms of expansion of 6/99 agreement; Exelixis will receive up-front and license payments of $20M, plus milestones and potential royalties; expanded agreement calls for at least $80M in additional research support; Bayer has exclusive marketing rights (1/00)

Lion Bioscience AG* (Germany)

Paradigm Genetics Inc. (PDGM)

Bioinformatics/development of informatics tools for metabolic profiling that predict the changes of biochemical pathways in plants and fungi; companies will develop phenotypic analysis tools


Project will broaden Lion's i-biology platform to the field of agriculture and will benefit Paradigm's AgDB system (1/00)

Methexis Genomics NV* (Belgium)

Sequenom Inc. (SQNM)

Research and development collaboration/use of companies' combined technologies to discover and assess genetic variations in targeted regions of human and plant genomes


Companies are collaborating to create and sell products using their combined technologies and may integrate Methexis' technology for discovering single nucleotide polymorphisms with agricultural applications into Sequenom's MassARRAY system (3/00)

Lynx Therapeutics Inc. (LYNX)

Aventis CropScience (unit of Aventis SA [France; NYSE:AVE])

Renewal of technology access agreement/Lynx's genomics discovery services for developing new crop varieties and other agricultural products, and for genomic mapping of certain plants and discovery of trait-associated single nucleotide polymorphisms


One-year renewal of 3/99 agreement providing non-exclusive access (3/00)

Neogen Corp. (NEOG)

Agdia Inc.*

Development collaboration/tests to determine if grains, oilseeds and vegetables are genetically modified


Companies established a joint venture to develop testing products (6/00)

Novalon Pharmaceutical Corp. (now a unit of Actelion [Switzerland])

Novartis Research Foundation (unit of Novartis AG [Switzerland; NYSE:NVS])

Research collaboration/use of Novalon's BioKey assays for genomic targets in the agricultural field


Novalon will provide BioKey assays for Novartis targets in return for up-front and research and development funding; technology access is non-exclusive (1/00)

Neurogen Corp. (NRGN)

Pfizer Inc. (NYSE:PFE)

License/development of Neurogen's drug candidates to treat obesity in companion animals; goal is to develop pills that will block neuropeptide Y neurotransmitters (NPY 1 and NPY 5)


New deal is the sixth between the companies in eight years; it expands the scope of 1995 agreement for NPY antagonists to treat obesity in humans; Neurogen will receive milestones milestones and royalties (6/00)

Paradigm Genetics Inc. (PDGM)

Monsanto Co. (unit of Pharmacia Corp.; NYSE: PHA)

Research collaboration/Paradigm will develop functional genomics data by analyzing the product of Monsanto's gene sequencing, bioinfomatics and functional genomics research, creating a product discovery platform for commercialization


Paradigm will receive $55M in committed payments; additional financial terms ND (1/00)

Paradigm Genetics Inc. (PDGM)

Renessen LLC (joint venture of Monsanto Co. [unit of Pharmacia Corp.; NYSE: PHA] and Cargill Inc.)

Expansion of research collaboration/application of functional genomics and bioinformatics expertise to the task of increasing yields of valuable grain components


Paradigm and Monsanto expanded 11/99 agreement to include Renessen (5/00)

Proteome Systems Ltd.* (Australia)

Dow AgroSciences LLC (subsidiary of Dow Chemical Co. [NYSE:DOW])

Research collaboration/use of Proteome's technology to characterize Dow proteins, map diversity of protein families and develop tools to elucidate novel biosynthetic pathways in plants; Proteome will also build several new proteomic databases for the program


Extension and expansion of multi-year agreement initiated 2/99 following achievement of several milestones in the first year of the collaboration (3/00)

SemBioSys Genetics* (Canada)

Novartis Agricultural Discovery Institute (unit of Novartis AG [Switzerland; NYSE:NVS)

Development collaboration/development of a product addressing nutraceutical, cosmeceutical and pharmaceutical markets using SemBioSys' oleosin technology (based on genetically engineering oilseeds to produce value-added proteins)


Novartis will fund development; SemBioSys will supply the product to Novartis, which will have exclusive rights (1/00)

Strategic Diagnostics Inc. (SDIX)

Novartis Seeds (unit of Novarts AG [Switzerland; NYSE:NVS])

Research and development/genetic tests for quality control in foundation seeds and crop breeding


Strategic Diagnostics will distribute the tests (6/00)

Symyx Technologies Inc. (SMMX)

Celanese AG (Germany; NYSE:CZ)

Extension of research collaboration/discovery of new catalysts to convert basic feed stocks into higher value-added commodity chemicals


Celanese will have exclusive rights to use catalysts discovered by Symyx in the defined field; Symyx will receive over $5M in research funding during the one-year extension (through 2/02) plus royalties on the sale of chemicals produced by the catalysts (5/15)

Trega Biosciences Inc. (TRGA)

DuPont Crop Protection (unit of DuPont [NYSE: DD])

Compound library access/Trega will supply small-molecule chemistry libraries through its Chem.Folio program


Trega will receive an up-front payment and potential milestones and royalties; agreement includes possibility of further collaboration in the future (1/00)

Univera Pharmaceuticals Inc.*

Unigen Ltd. (Korea)

License and research collaboration/transfer of Univera's PhytoLogix and PhytoGenEx technologies to Unigen and the sharing of future technical improvements


Univera received a $1M license fee and will receive royalties on future improvements; as part of the agreement, the companies will collaborate on plant screening (5/00)


This chart contains information on new corporate agreements in agricultural biotechnology covering the time between 1/1/00 and 6/30/00.

AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; NM = Nouveau Marche; OTC BB = Over The Counter Bulletin Board

ND = Not disclosed, reported and/or available

* Private companies are indicated with an asterisk.

No Comments